Repaglinide is a diabetes drug that may be used alone or in combination with other antihyperglycemic drugs. It has been approved for use in patients with type I diabetes and has been used in patients with chronic kidney disease. It is considered to be a safe alternative to metformin and sulfonylureas. Patients should follow the instructions of their physicians when taking the drug. They should also wear a diabetic identification bracelet so that they can be treated properly in case of an emergency. Their pharmacist should also be able to answer any questions regarding the prescription.<\/p>\n\n\n\n
Repaglinide is an antihyperglycemic drug for the treatment of type 2 diabetes. It reduces blood glucose levels by stimulating the pancreas to release more insulin. The medication is inexpensive, but it has some drawbacks. For one, it requires a significant amount of self-monitoring, requiring an up-titration every two weeks. Additionally, repaglinide has a limited license and many combinations of the drug with other glucose-lowering drugs are ‘off-license'. This is one of the reasons it is withdrawn from the guideline.<\/p>\n\n\n\n
The National Institute for Health and Care Excellence (NICE) recently reopened its consultation on diabetes guidelines. It had received criticism over its previous drafts, including accusations of putting an excessive emphasis on cutting costs and not on the care of patients. Critics have also criticized NICE's position on repaglinide, a drug from Novo Nordisk in the meglitinide class.<\/p>\n\n\n\n
Repaglinide is an insulin secretagogue that works by binding to the receptors on the beta cells of the pancreas. It also blocks a potassium channel on beta cells, a similar mechanism to sulfonylureas. However, it is important to note that repaglinide should not be used in conjunction with sulfonylurea drugs.<\/p>\n","protected":false},"excerpt":{"rendered":"
The NICE guidelines for diabetes are being updated to incorporate more real-world data and observational studies. Previously, NICE had largely used randomised control trials and Cochrane reviews for evidence. The latest update reflects the views of 32 stakeholders, who supported the changes and proposed additional areas for further research. SGLT2 inhibitors The Nice guidelines for […]<\/p>\n","protected":false},"author":2,"featured_media":2110,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[77],"tags":[374,375,61,373,376],"_links":{"self":[{"href":"https:\/\/survivingdiabetes.com\/wp-json\/wp\/v2\/posts\/2100"}],"collection":[{"href":"https:\/\/survivingdiabetes.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/survivingdiabetes.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/survivingdiabetes.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/survivingdiabetes.com\/wp-json\/wp\/v2\/comments?post=2100"}],"version-history":[{"count":1,"href":"https:\/\/survivingdiabetes.com\/wp-json\/wp\/v2\/posts\/2100\/revisions"}],"predecessor-version":[{"id":2112,"href":"https:\/\/survivingdiabetes.com\/wp-json\/wp\/v2\/posts\/2100\/revisions\/2112"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/survivingdiabetes.com\/wp-json\/wp\/v2\/media\/2110"}],"wp:attachment":[{"href":"https:\/\/survivingdiabetes.com\/wp-json\/wp\/v2\/media?parent=2100"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/survivingdiabetes.com\/wp-json\/wp\/v2\/categories?post=2100"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/survivingdiabetes.com\/wp-json\/wp\/v2\/tags?post=2100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}